Therapeutics

Valerie Morissette, Executive Vice President of Research and Development and Chief Scientific Officer of Eliem Therapeutics, Inc. (NASDAQ:ELYM), sold a significant number of shares of the company. On July 3, 2024, Morissette disposed of…

On Friday, HC Wainwright maintained a Buy rating on shares of Lava Therapeutics NV (NASDAQ: LVTX), with a $6.00 price target. Lava Therapeutics, a biotechnology company, recently participated in the 2nd Annual Immune Cell Engager…

New York, May 16, 2024 /PRNewswire/ -- Selous Therapeutics (NASDAQ:), Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (“CNS”)…

Amicus (NASDAQ:) Therapeutics, Inc. (NASDAQ:FOLD) President and CEO Bradley L. Campbell recently engaged in transactions involving the company's common stock, according to a new filing with the Securities and Exchange Commission. On…

On Tuesday, Morgan Stanley began coverage on Dyne Therapeutics (NASDAQ:DYN) stock, assigning an Overweight rating and setting a price target of $40.00. The firm's assessment hinges on the promising early data from the company's leading drug…

BOSTON and ATLANTA - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company engaged in developing treatments for Parkinson's disease and related disorders, has announced significant advancements in its clinical trials,…

(Reuters) -Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. Shares…

© Reuters. In a strategic move, Akari Therapeutics (NASDAQ: NASDAQ:) has announced today a private placement agreement with select current investors, aiming to raise approximately $1.615 million. The transaction involves the sale of…

© Reuters. DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ:), a biopharmaceutical company specializing in precision oncology, announced today that it has entered into a securities purchase agreement with healthcare-focused…

With Viking Therapeutics (NASDAQ: VKTX) stock exploding skyward by 528% over the last 12 months, it's easy to wonder if the opportunity to buy its stock is too good to be true -- and a bit too late.But in this case, there's actually a…